What's Trending in Stocks Right Now
Discover which stock market news stories are capturing the most attention today. This page shows you the most-viewed articles on StockTitan, updated every minute based on real visitor traffic. See what tens of thousands of traders and investors are reading right now.
Why this matters: When a news story suddenly gets massive readership, it often indicates significant market interest in that stock or sector. By tracking the most popular articles, you can quickly identify which companies and events are drawing investor attention and potentially moving markets.
This isn't editorial content or sponsored placement—it's based purely on reader activity. Every story below earned its position through actual page views from real visitors, making this an authentic snapshot of what the trading community finds most interesting. Whether it's earnings reports, FDA decisions, merger news, or market analysis, the most-read stories rise to the top.
Updated Every Minute: Market sentiment shifts quickly. This ranking is recalculated every 60 seconds to reflect the latest reading trends. What's trending now could be completely different in an hour as new stories break and capture attention.
Rocket Lab (Nasdaq: RKLB) completed its second dedicated mission for the Japan Aerospace Exploration Agency, "Kakushin Rising", launching from Launch Complex 1 in New Zealand on April 23, 2026 at 3:09 p.m. NZT to deploy eight JAXA spacecraft.
Payloads included educational small sats, an ocean‑monitoring satellite, an ultra‑small multispectral camera demonstrator, and a deployable origami antenna that can unfurl to 25× its packed size. This was Rocket Lab's 8th launch of 2026 and 87th overall.
- Deployed 8 JAXA spacecraft successfully on one mission
- Second dedicated mission for JAXA, strengthening the partnership
- Launch executed from Launch Complex 1 at 3:09 p.m. NZT
- Demonstrated a 25× origami deployable antenna technology
- Rocket Lab's 8th launch of 2026 and 87th overall
- None.
STMicroelectronics (NYSE: STM) reported Q1 2026 U.S. GAAP net revenues of $3.10 billion, gross margin of 33.8%, operating income of $70 million, and net income of $37 million ($0.04 diluted EPS). Non-U.S. GAAP net income was $122 million ($0.13 EPS).
Management expects Q2 2026 mid-point net revenues of $3.45 billion and U.S. GAAP gross margin of 34.8%. The release notes the completed acquisition of NXP’s MEMS sensor business and a multi-year AWS commercial engagement.
- Net revenues +23.0% year-over-year to $3.10B
- Non-U.S. GAAP net income of $122M and EPS $0.13
- Q2 2026 mid-point revenue guidance of $3.45B (+11.6% sequential)
- Datacenter revenue target: >$500M for 2026 and >$1B for 2027
- Completed acquisition of NXP MEMS sensor business
- Q1 free cash flow negative $723M, including $895M acquisition cash-out
- Net financial position (non-U.S. GAAP) declined to $2.00B from $2.79B
- Operating income impacted by $71M restructuring and $30M PPA charges
- Power & Discrete segment operating loss widened to $84M (-21.5% margin)
Altimmune (Nasdaq: ALT) priced an oversubscribed underwritten offering expected to raise approximately $225 million in gross proceeds. The deal comprises 64,250,000 common shares and accompanying warrants, plus up to 10,750,000 pre-funded warrants and accompanying warrants.
Combined offering prices are $3.00 per share-plus-warrant and $2.999 per pre-funded-warrant-plus-warrant; warrants exercise at $3.00, expire on the fifth anniversary or 45 days after a Phase 3 pemvidutide MASH successful readout. Proceeds are intended to fund the Phase 3 MASH trial, working capital and general corporate purposes.
- Gross proceeds of approximately $225 million to fund development
- 64,250,000 common shares sold with accompanying warrants
- Warrants exercisable at $3.00 with up to five-year term and accelerated 45-day trigger
- Proceeds earmarked to fund upcoming Phase 3 pemvidutide MASH trial
- Issuance of up to 150,000,000 instruments (shares, pre-funded warrants, and accompanying warrants) may dilute existing shareholders
- Exercise price of $3.00 on warrants could pressure share price if market trades below that level
- Offering subject to market and customary closing conditions; no assurance the offering will close as expected
Woodside Energy (ASX:WDS) issued an AGM address release dated April 23, 2026, delivered in Perth. The announcement complies with Listing Rules and was authorised for market release by Woodside's Disclosure Committee.
This note confirms procedural release and availability of the AGM address to shareholders and the market.
- None.
- None.
Roche (OTCQX: RHHBY) reported Group sales of CHF 14.7bn in Q1 2026: +6% at constant exchange rates, -5% in CHF and +9% in USD. Pharmaceuticals grew +7% CER (CHF 11.5bn) and Diagnostics +3% CER (CHF 3.3bn). Key clinical wins include positive phase III results for fenebrutinib (MS) and Gazyva (membranous nephropathy), CE mark for Elecsys NfL, launch of an NVIDIA AI factory, a definitive agreement to acquire SAGA Diagnostics, and a dividend increase to CHF 9.80. Outlook: mid single‑digit Group sales growth (CER) and high single‑digit core EPS growth (CER) for 2026.
- Group sales CHF 14.7bn, +6% at CER
- Pharmaceuticals sales CHF 11.5bn, +7% at CER
- CE mark for Elecsys NfL blood test
- Positive phase III for fenebrutinib in MS
- Definitive agreement to acquire SAGA Diagnostics
- Dividend increased to CHF 9.80 per share
- -5% in CHF due to Swiss franc appreciation
- Diagnostics sales -7% in CHF despite +3% CER
- US reported sales down -9% in CHF vs 2025
- China pricing reforms pressured Asia‑Pacific Diagnostics (-15% in CHF)
XCF Global (NASDAQ:SAFX) announced CEO Chris Cooper will speak at the Water Tower Research Circular Economy: Investing in SAF, CCUS, and Waste-to-Value symposium on Thursday, April 23, 2026 at 6:00 AM ET. The three-part symposium covers XCF's background, growth strategy, commercial partnerships and offtake agreements, regulatory developments, and geopolitical factors. The event is hosted by Shawn Severson and Peter Gastreich and will be available via podcast.
- None.
- None.
Exicure (Nasdaq: XCUR) announced a co-development agreement with Adbiotech (KOSDAQ: 179530) on April 22, 2026, to explore combination therapies using Burixafor (GPC-100) across sickle cell disease, AML, and solid tumors.
Under the deal, Adbiotech will run in vivo and preclinical validation while Exicure supplies Burixafor and leads clinical and regulatory strategy. Burixafor completed a Phase 2 trial in multiple myeloma last year. Parties may advance selected programs to IND-enabling studies and clinical trials, subject to further agreements and funding; budget, IP, and commercialization terms remain to be finalized.
- Signed co-development agreement with Adbiotech dated April 22, 2026
- Burixafor completed a Phase 2 trial in multiple myeloma
- Adbiotech to perform in vivo studies and preclinical validation
- Exicure to lead clinical and regulatory strategy for Burixafor
- Development advancement subject to further definitive agreements and funding
- Key terms—budget, IP, and commercialization—are not yet finalized
- Advancement to IND-enabling studies is conditional, not guaranteed
Black Titan (NASDAQ:BTTC) outlines rapid institutional adoption of DeFi-as-a-Service (DaaS) primitives: automated yield routing, Restaking-as-a-Service (RaaS), and tokenized private credit. Key developments include payment-processor stablecoin sweep APIs, custodial Liquid Restaking Token gateways, a 15% MoM rise in tokenized private credit originations on Avalanche, and MiCA-driven euro-stablecoin lending expansion.
The note flags prime brokers absorbing smart-contract compliance risk and forecasts middleware growth, regulatory bifurcation on yield products, and SME treasury migration to stablecoin-native neobanks by Q3 2026.
- 15% month-over-month increase in tokenized private credit originations
- Neobanks can offer 8%+ private credit yields to premium clients
- Payment gateways enable automated stablecoin sweep accounts for merchant liquidity
- Custodial RaaS APIs package staking yield into compliant interfaces
- Potential regulatory bifurcation could impose distinct capital requirements on yield products
- Neobanks face protocol slashing and smart-contract risk when offering RaaS without prime-broker intermediation
Dassault Systèmes (DASTY) reported Q1 2026 results in line with objectives and confirmed its FY26 outlook. Total revenue and software revenue rose 3% in constant currencies to about €1.51B. ARR reached €4.37B (+6%). IFRS operating cash flow was €949M (+22%). Non-IFRS operating margin was 30.3% and non-IFRS diluted EPS was €0.30 (+4% in constant currencies). The company reaffirmed FY26 non-IFRS guidance, including revenue €6.29–€6.41B and EPS €1.30–€1.34.
- Total revenue +3% to €1.51B (constant currencies)
- Annual Run Rate (ARR) +6% to €4.37B
- IFRS operating cash flow €949M, up 22%
- Non-IFRS operating margin at 30.3%
- Cloud software revenue +8%; 3DEXPERIENCE revenue +7%
- IFRS reported revenue down 4% year-over-year (€1,509.2 vs €1,573.0)
- Non-IFRS diluted EPS reported down 6% to €0.30 (but +4% ex-FX)
- Life Sciences software revenue down 3% to €259M; MEDIDATA headwinds
- Non-IFRS operating income decreased 6% as reported